Latest Novocure Limited Stories
Trial will test the potential synergy between a taxane and TTFields in the treatment of recurrent ovarian cancer ST. HELIER, Jersey, Oct.
The supplement is intended to provide an overview of available knowledge regarding the use of NovoTTF Therapy for the treatment of recurrent glioblastoma, as well as its development for the treatment
Designation of High Unmet Medical Need allows for accelerated review of regulatory submissions in Japan, the second largest medical device market in the world ST.
Japanese Society of Neuro-Oncology calls for rapid approval by the Japanese Ministry of Health and Welfare (MHLW) ST. HELIER, Jersey, Aug.
Physicians at 15 leading brain cancer centers in 8 countries certified to provide NovoTTF Therapy to recurrent glioblastoma patients on prescription order LUCERNE, Switzerland, July
Analysis of PRiDe, a U.S.
A registry of 457 recurrent glioblastoma patients shows that patients treated commercially with NovoTTF Therapy in 2012 and 2013 achieved the longest median overall survival yet shown in non-experimental
HAIFA, Israel, April 3, 2014 /PRNewswire/ -- Novocure, a commercial stage oncology company, announced today that new, pre-clinical data demonstrating the anti-tumor effects of NovoTTF(TM) Therapy will
The NovoTAL System Enables Certified Physicians to Plan and Individualize NovoTTF(TM) Therapy for Recurrent Glioblastoma Patients NEW YORK, Feb.
HAIFA, Israel, Jan.
- A hairdresser.